#Cell_and_Gene_Therapy_(CGT) has rapidly evolved from a niche innovation into a mainstream healthcare solution, fundamentally transforming how we diagnose, treat, and manage rare and chronic diseases. By 2025, the adoption of cell and gene therapy has reached a pivotal stage, with an increasing number of approved therapies improving patient outcomes across oncology. Read More: https://m2squareconsultancy.com/blogs/global-healthcare